prikaz prve stranice dokumenta CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience
  Download
PDF 137.17 KB
Scientific paper - Original scientific paper
CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience
Collegium Antropologicum, 34 (2010), 1; 171-175. urn:nbn:hr:105:128699
Bilić, Ernest; Femenić, Ranka; Konja, Josip; Šimat, Marija; Dubravčić, Klara; Batinić, Drago; Ries, Sunčica; Rajić, Ljubica

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Bilić, E., Femenić, R., Konja, J., Šimat, M., Dubravčić, K., Batinić, D. ... Rajić, Lj. (2010). CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience . Collegium Antropologicum, 34. (1), 171-175. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:128699

Bilić, Ernest, et al. "CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience ." Collegium Antropologicum, vol. 34, no. 1, 2010, pp. 171-175. https://urn.nsk.hr/urn:nbn:hr:105:128699

Bilić, Ernest, Ranka Femenić, Josip Konja, Marija Šimat, Klara Dubravčić, Drago Batinić, Sunčica Ries and Ljubica Rajić. "CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience ." Collegium Antropologicum 34, no. 1 (2010): 171-175. https://urn.nsk.hr/urn:nbn:hr:105:128699

Bilić, E., et al. (2010) 'CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience ', Collegium Antropologicum, 34(1), pp. 171-175. Available at: https://urn.nsk.hr/urn:nbn:hr:105:128699 (Accessed 02 May 2024)

Bilić E, Femenić R, Konja J, Šimat M, Dubravčić K, Batinić D, and sur.. CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience . Collegium Antropologicum [Internet]. 2010 March [cited 2024 May 02];34(1):171-175. Available at: https://urn.nsk.hr/urn:nbn:hr:105:128699

E. Bilić, et al., "CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience ", Collegium Antropologicum, vol. 34, no. 1, pp. 171-175, March 2010. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:128699. [Accessed: 02 May 2024]

Metadata
Title (english)CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience
Title (croatian)CD20 pozitivni B ne-Hodgkinovi limfoni u djece (B-NHL): morfologija, imunofenotipizacija i novija terapijska dostignuća: iskustva jednog centra
AuthorErnest Bilić
AuthorRanka Femenić
AuthorJosip Konja
AuthorMarija Šimat
AuthorKlara Dubravčić
AuthorDrago Batinić
AuthorSunčica Ries
AuthorLjubica Rajić
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Lymphomas represent the third most common group of cancers in childhood and adolescence, mature B non Hodgkin’s lymphoma (B-NHL) accounting for up to 60% of newly diagnosed patients. The diagnosis of specific entities of B-NHL is based on well-defined morphologic analysis, immunophenotyping, cytogenetics and molecular genetics, which determine the optimal treatment strategy. In adult population a major turning point in treatment of B-NHL has been achieved since rituximab, in combination with CHOP has improved the survival rate up to 19%. Rituximab is a chimeric monoclonal antibody that targets CD20, a transmembrane calcium channel expressed on normal and malignant B-cells that mediates cytotoxic, apoptotic and anti-proliferative effects. The effect of rituximab in pediatric population is still not well enough investigated. Based on morphology and immunophenotype of malignant cells, seven children with B-NHL in our institution were eligible for treatment with modified B-NHL-Berlin-Frankfurt-Münster (BFM)-95-based protocol with rituximab administered on day -5. The complete remission was achieved in all seven patients. Six patients are still in complete remission at least 12 months after having finished chemotherapy and one patient relapsed two months after the last cycle and subsequently died. Major adverse effects observed during treatment were prolonged B-cell depletion and myelosupression. Rituximab in combination with B-NHL-BFM-95 protocol was otherwise well tolerated and proved to be effective in children and adolescents with B-NHL. The number of our patients is too small and the follow-up of a larger group of patients will help in defining the role of rituximab in the treatment of childhood B-NHL.
Abstract (croatian)
Limfomi su treći najčešći maligni tumor u djece i adolescenata, od čega na B ne-Hodgkinov (B-NHL) limfom otpada oko 60% novodijagnosticiranih slučajeva. Dijagnoza B-NHL-a temelji se na morfološkoj analizi, imunofenotipizaciji, citogenetskoj analizi i na molekularnoj genetici. Bitan napredak u liječenju B-NHL-a u odraslih postignut je dodavanjem rituximaba uz protokol CHOP nakon čega je došlo do poboljšanja preživljenja za oko 19%. Rituximab je kimerično monoklonsko protutijelo koje se veže za CD20, transmembranski receptor koji se nalazi na normalim i malignim B limfocitima i ima citotoksični, proapoptotički i antiproliferativni učinak. Učinak rituximaba u djece još je uvijek nepoznanica. Temeljem analize uzoraka tkiva kod sedmero djece postavljena je dijagnoza B-NHL-a. Svi su liječeni u našoj ustanovi prema protokolu liječenja B-NHL-BFM 95 sa dodatkom rituximaba koji je primjenjen pet dana prije početka kemoterapije. Kompletna remisija je postignuta u svih sedam pacijenata. Šestero pacijenata se još uvijek nalazi u kompletnoj remisiji najmanje 12 mjeseci od prestanka liječenja. Jedan pacijent je dobio relaps dva mjeseca po prestanku terapije i kasnije umro. Glavne neželjene nuspojave terapije bile su produljeni nedostatak B limfocita i produljeno potiskivanje rada koštane srži. Cjelokupno gledajući djeca su dobro podnosila rituximab sa protokolom B-NHL-BFM-95. Broj pacijenata u ovom radu je premali i za konačne zaključke bit će potrebno praćenje veće skupine pacijenata.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCollegium Antropologicum
Numberingvol. 34, no. 1, pp. 171-175
p-ISSN0350-6134
URN:NBNurn:nbn:hr:105:128699
Publication2010-03
Document URLhttps://hrcak.srce.hr/51259
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 11:44:03